{"id":"W2999435318","doi":"10.1016/s0923-7534(20)34326-x","title":"Randomized Phase IIIB Trial of Temsirolimus and Bevacizumab Versus Interferon and Bevacizumab in Metastatic Renal Cell Carcinoma: Results from Intoract","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Temsirolimus; Bevacizumab; Renal cell carcinoma; Oncology; Internal medicine; Randomized controlled trial; Discovery and development of mTOR inhibitors; Chemotherapy; PI3K/AKT/mTOR pathway","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002762798,0.002167814,0.003456723,0.0004212572,0.0005704293,0.001474593,0.0010982,0.001838704,0.008721957],"category_scores_gemma":[0.002688459,0.0007050504,0.002623727,0.0005928622,0.001630523,0.001999535,0.0006597891,0.005092162,0.001617017],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001523463,"about_ca_system_score_gemma":0.002144364,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002215081,"about_ca_topic_score_gemma":0.004241869,"domain_scores_codex":[0.9989167,0.0006385226,0.00005078258,0.0001760095,0.00005851905,0.0001595608],"domain_scores_gemma":[0.9981159,0.0004970874,0.0004003042,0.0001962388,0.0001023729,0.0006882119],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9821557,0.003136116,0.0004710241,0.0001766421,0.0008182655,0.0000204071,0.00004017204,0.0004428981,0.001449087,0.000113986,0.001129543,0.01004599],"study_design_scores_gemma":[0.9652592,0.03155022,0.001328596,0.00001454629,0.0004319347,0.00002872143,0.00002133555,0.0003506572,0.0002053123,0.0001829397,0.0006156655,0.00001095771],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9835848,0.003787035,0.0009839697,0.002025429,0.0008410097,0.002889181,0.002330071,0.000182694,0.003375838],"genre_scores_gemma":[0.9759675,0.002358337,0.003050689,0.00283667,0.00077229,0.004443,0.004018759,0.0001044945,0.006448419],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008721957,"threshold_uncertainty_score":0.02917784,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1350490563877559,"score_gpt":0.3991791572432816,"score_spread":0.2641301008555257,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}